Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Recently, the U.S. Food and Drug Administration (FDA) approved neoadjuvant immunotherapy plus chemotherapy for the treatment of resectable non-small-cell lung carcinoma (NSCLC) due to the clinical benefits reported in several clinical trials. In these settings, the pathological asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Frank, Parra, Edwin Roger, Wistuba, Ignacio Ivan, Haymaker, Cara, Solis Soto, Luisa Maren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179283/
https://www.ncbi.nlm.nih.gov/pubmed/35681755
http://dx.doi.org/10.3390/cancers14112775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179283/
https://www.ncbi.nlm.nih.gov/pubmed/35681755
http://dx.doi.org/10.3390/cancers14112775

Ejemplares similares